{"id":9012,"date":"2020-04-15T11:22:46","date_gmt":"2020-04-15T09:22:46","guid":{"rendered":"https:\/\/www.resist-cluster.de\/?page_id=9012"},"modified":"2022-02-02T13:02:48","modified_gmt":"2022-02-02T12:02:48","slug":"prof-dr-bodo-grimbacher","status":"publish","type":"page","link":"https:\/\/www.resist-cluster.de\/en\/about-us\/research-team-2\/prof-dr-bodo-grimbacher\/","title":{"rendered":"Prof. Dr. Bodo Grimbacher"},"content":{"rendered":"

<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/a><\/span><\/div>

Prof. Dr. Bodo Grimbacher participates in\u00a0RESIST research project A2.<\/p>\n<\/div>

<\/div><\/div><\/div>

\n\n\n
<\/i><\/td>\nMy Research Interest in RESIST<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/h1><\/div>

Currently, more than 350 genes are known to cause primary immunodeficiencies (PID). However, depending on the cohort studied, these 350 genes only explain about 15-60% of patients. Hence, other causative or contributing factors, such as epigenetic profiles, the regulation of gene expression, or the gut microbiome, need to be studied. Our main objectives in RESIST are: reducing the number of unsolved cases – since the majority of patients with immunodeficiency are currently undiagnosed -, improving our understanding on how the epigenome works and its role in primary immunodeficiency disease and\u00a0understanding the relationship between the gut microbiome and disease severity and comorbidity in PID patients with malignancies, autoimmunity or inflammation.<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
<\/i><\/span>Contact<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/path><\/svg><\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div>

Prof. Grimbacher about his scientific work<\/h1><\/div>